Other substances

Shikonin

A hydroxynaphtoquinone.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Natural product

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Shikonin on PubChem

Structure image - Shikonin

CC(=CC[C@H](C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Discovering drugs to treat coronavirus disease 2019 (COVID-19).	in silico			Feb/22/2020
Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode 3CLpro Small molecule In vitro	X-ray crystallography	9.51	SARS-CoV-2 3C-like protease binding observed using co-crystalization and x-ray crystallography.	Oct/29/2020

AI-suggested references

Link	Publication date
Discovery of potent inhibitors for Mpro enzyme of SARS-COV2 by multi-stage in-silico screening of Alkannin/shikonin.	Jun/17/2021
Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors.	Oct/09/2020
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays	May/05/2021
Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies	Jan/21/2021
Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors.	Aug/18/2021
Exploration of SARS-CoV-2 3CLpro Inhibitors by Virtual Screening Methods, FRET Detection, and CPE Assay	Jul/01/2021
Structure-Based Discovery and Structural Basis of a Novel Broad-Spectrum Natural Product against the Main Protease of Coronavirus	Sep/29/2021